154612-58-5

Basic information

• Product Name: (2S,4R)-1-[(2R,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy- 4-phenyl-butyl]-4-pyridin-4-ylsulfanyl-N-tert-butyl-piperidine-2-carbo xamide
• Synonyms: (2S,4R)-1-[(2R,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy- 4-phenyl-butyl]-4-pyridin-4-ylsulfanyl-N-tert-butyl-piperidine-2-carbo xamide
• CAS NO: 154612-58-5
• Molecular Formula: C35H46N4O4S
• Molecular Weight: 618.83
• Mol File: 154612-58-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 858.7°Cat760mmHg
• Flash Point: 473.1°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 2.02E-31mmHg at 25°C
• Refractive Index: 1.616
• PKA: 13.91±0.46(Predicted)
• CAS DataBase Reference: (2S,4R)-1-[(2R,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy- 4-phenyl-butyl]-4-pyridin-4-ylsulfanyl-N-tert-butyl-piperidine-2-carbo xamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-[(2R,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy- 4-phenyl-butyl]-4-pyridin-4-ylsulfanyl-N-tert-butyl-piperidine-2-carbo xamide(154612-58-5)
• EPA Substance Registry System: (2S,4R)-1-[(2R,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy- 4-phenyl-butyl]-4-pyridin-4-ylsulfanyl-N-tert-butyl-piperidine-2-carbo xamide(154612-58-5)

Safety Data

• Hazardous Substances Data: 154612-58-5(Hazardous Substances Data)

Usage

Description

(2S,4R)-1-[(2R,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenyl-butyl]-4-pyridin-4-ylsulfanyl-N-tert-butyl-piperidine-2-carboxamide is a complex chiral compound with a molecular structure that features various functional groups such as amides, piperidines, pyridines, and phenyls. It has four stereocenters, indicated by the letters S and R, which contribute to its unique properties. (2S,4R)-1-[(2R,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy4-phenyl-butyl]-4-pyridin-4-ylsulfanyl-N-tert-butyl-piperidine-2-carbo xamide holds potential pharmacological significance due to its structural characteristics, making it a candidate for use as an active pharmaceutical ingredient in drug development. Further research and experimentation are required to determine its specific biological activity and potential applications.

Uses

Used in Pharmaceutical Industry:
(2S,4R)-1-[(2R,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenyl-butyl]-4-pyridin-4-ylsulfanyl-N-tert-butyl-piperidine-2-carboxamide is used as a potential active pharmaceutical ingredient for drug development due to its complex molecular structure and chiral properties. Its specific biological activity and therapeutic potential would need to be explored through additional research and clinical trials.

InChI:InChI=1/C35H46N4O4S/c1-24-10-9-11-25(2)33(24)43-23-32(41)37-29(20-26-12-7-6-8-13-26)31(40)22-39-19-16-28(44-27-14-17-36-18-15-27)21-30(39)34(42)38-35(3,4)5/h6-15,17-18,28-31,40H,16,19-23H2,1-5H3,(H,37,41)(H,38,42)/t28-,29+,30+,31-/m1/s1

Upstream product

• 264884-00-6 {(1S,2R)-1-Benzyl-3-[(2S,4R)-2-tert-butylcarbamoyl-4-(pyridin-4-ylsulfanyl)-piperidin-1-yl]-2-hydroxy-propyl}-carbamic acid tert-butyl ester 
• 6279-47-6 ethyl 2-(2,6-dimethylphenoxy)acetate 
• 576-26-1 2.6-dimethylphenol 
• 264883-98-9 2-tert-butylcarbamoyl-4-(pyridin-4-ylsulfanyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 264884-06-2 2-tert-butylcarbamoyl-4-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester 
• 154612-85-8 (2S,4R)-4-(Pyridin-4-ylsulfanyl)-piperidine-2-carboxylic acid tert-butylamide 
• 175671-47-3 (2S,4R)-4-hydroxypipecolic tert-butylamide 
• 4556-23-4 pyridine-4-thiol 
• 13335-71-2 2-(2,6-dimethylphenoxy)acetic acid 

Relevant articles and documents

2',6'-Dimethylphenoxyacetyl: A new achiral high affinity P3-P2 ligand for peptidomimetic-based HIV protease inhibitors

Starting from palinavir (1), our lead HIV protease inhibitor, we have discovered a new series of truncated analogues in which the P3-P2 quinaldic-valine portion of 1 was replaced by 2',6'-dimethylphenoxyacetyl. With EC50's in the 1-2 nM range, some of these compounds are among the most potent inhibitors of HIV replication in vitro, reported to date. One of the most promising members in this series (compound 27, BILA 2185 BS) exhibited a favorable overall pharmacokinetic profile, with 61% apparent oral bioavailability in rat. X-ray crystal structures and molecular modeling were used to rationalize the high potency resulting from incorporation of this structurally simple, achiral ligand into the P3-P2 position of hydroxyethylamine-based HIV protease inhibitors.